Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $3.3333.

RVPH has been the subject of several research reports. Chardan Capital reiterated a “buy” rating and set a $2.00 price objective on shares of Reviva Pharmaceuticals in a research note on Monday, January 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Wednesday, October 8th. D. Boral Capital reaffirmed a “buy” rating and set a $2.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Finally, Wall Street Zen upgraded Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 27th.

Institutional Trading of Reviva Pharmaceuticals

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in shares of Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after acquiring an additional 29,063 shares in the last quarter. NewEdge Advisors LLC acquired a new stake in Reviva Pharmaceuticals during the 1st quarter valued at approximately $58,000. XTX Topco Ltd purchased a new stake in Reviva Pharmaceuticals during the 2nd quarter worth approximately $31,000. Lido Advisors LLC purchased a new stake in Reviva Pharmaceuticals during the 3rd quarter worth approximately $37,000. Finally, Millennium Management LLC raised its position in shares of Reviva Pharmaceuticals by 15.0% in the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after purchasing an additional 223,178 shares in the last quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Price Performance

Shares of NASDAQ:RVPH opened at $0.34 on Wednesday. The business has a 50-day moving average of $0.47 and a two-hundred day moving average of $0.48. The firm has a market capitalization of $38.87 million, a PE ratio of -0.73 and a beta of 0.08. Reviva Pharmaceuticals has a 12 month low of $0.25 and a 12 month high of $2.15.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.05. As a group, research analysts anticipate that Reviva Pharmaceuticals will post -0.97 earnings per share for the current year.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.